A systematic review of Helicobacter pylori eradication therapy - The impact of antimicrobial resistance on eradication rates

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 8, 1999, Pages 1047-1055

  Houben, M H M G ^a   Van De Beek, D ^a   Hensen, E F ^a   De Craen, A J M ^a   Rauws, E A J ^a   Tytgat, G N J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; METRONIDAZOLE; NITROIMIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL;

EID: 0032838090     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00555.x     Document Type: Article

References (50)

1. 1 Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritits and peptic ulceration. Lancet 1984; 1: 1311-5.
2. 2 Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335(8700): 1233-5.
3. 3 Bayerdorffer E, Neubauer A, Rudolf B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 335(8965): 1591-4.
4. 4 Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma [see comments]. New England J Med 1127-31; 1991: 325 (16): .
5. 5 Van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: A review of the world literature, Helicobacter. 1996; 1: 6-19.
6. 6 Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 43-53.
7. 7 Graham DY. Antibiotic Resistance in Helicobarter Pylori - Implications For Therapy. Gastroenterol 1998; 115(5): 1272-7.
8. 8 Goodwin CS, Blincow ED, Warren JR, Waters TE, Sanderson CR, Easton L. Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa. J Clin Pathol 1985; 38(10): 1127-31.
9. 9 Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter Pylori. Gastroenterol 1998; 115(5): 1278-82.
10. 10 Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori [see comments]. J Antimicrobial Chemotherapy 1992; 29(2); 115-20.
11. 11 Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J Antimicrobial Chemotherapy 1995; 35(6): 751-64.
12. 12 Weel JF, van der Hulst RW, Gerrits Y, Tytgat GN, van der Ende A, Dankert J. Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease. J Clin Microbiol 1996; 34(9): 2158-62.
13. 13 Weissfeid A, Haber M, Rose P, Kids S, Siejman N. Geographical distribution in the United Sates of primary resistance to clarithromycin and metronidazole in patient infected with Helicobacter pylori. Gastroenterol 1997; 112: A328(Abstract).
14. 14 Glupczynski Y, Langenberg W, Dankert A, et al. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European J Clin Microbiol Infectious Dis 1992; 11(9): 777-81.
15. 15 Broutet N, Guillon F, Sauty E, Lethuaire D, Megraud F. Survey of the in vitro susceptibility of Helicobarter pylori to antibiotics in France. Gastroenterol 1998; 114: A81 (Abstract).
16. 16 Penston JG, McColl KE. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43(3): 223-43.
17. 17 Megraud F, Doermann HP, Clinical Relevance of resistant strains of Helicobacter Pylori - a review of current data. Gut 1998; 43(Suppl. 1): S61-S65.
18. 18 Lind T, Megraud F, Bardhan KD, et al. The mach2 study: antimicrobial resistance in Helicobacter pylori therapy - the impact of omeprazole. Gut 1997; 41(Suppl. 1): A89(Abstract).
19. 19 Buckley MJ, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Digestive Dis Sci 1997; 42(10): 2111-5.
20. 20 Misiewicz JJ, Harris AW, Bardhan KD, et al. One week triple therapy for Helicobacter pylori: a rnulticentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997; 41(6): 735-9.
21. 21 Kist M, Strobel S, Folsch UR, et al. Prospective assessment of the impact of primary antimicrobial resistances on cure rales of Helicobacter pylori infections. Gut 1997; 41(Suppl. 1): A90(Abstract).
22. 22 Xia HX, Buckley M, Hyde DK, Keane CT, O'Morain C. Effects of antibiotic-resistance on clarithromycin-combined triple therapy for Helicobacter pylori. Gut 1995; 37(Suppl. 1): A55(Abstract).
23. 23 Georgopoulos S, Mentis A, Karatapanis S. Comparison of the efficacy of two, short-term, triple therapies based on clarithromycin, in the eradication of Helicobacter pylori (HP): a ramdomized study. Cut 1996; 39(Suppl. 2): A34( Abstract).
24. 24 Powell KU, Bell GD, Bowden AF, Trowell JE, Joncs PH. An effective one-week Helicobacter pylori eradication therapy using omeprazole, clarithromycin and metronidazole. Br J Clin Res 1995; 6(85-90): 85-90.
25. 25 Moayyedi P, Ragunathan PL, Mapstone N, Axon ATR, Tompkins DS. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1998; 33(2): 160-3.
26. 26 Houben MHMG, Hensen EF, van't Hoff BWM, et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in the treatment of Helicobacter pylori (Hp) in metronidazole resistant or sensitive patients. Gastroenterol 1998; 114(4): A153 (G0628).
27. 27 Goh KL, Parasakthi N, Chuah SY, Cheah PL, Lo YL, Chin SC. Comparison of two 1-weck low-dose omeprazole triple therapies - Optimal treatment for Helicobacter pylori infection. Alimentary Pharmacol Therapeutics 1997; 11(6): 1115-8.
28. 28 Lerang F, Moum B, Haug JB, et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997; 92(2): 248-53.
29. 29 Schwartz H, Krause R, Siepman N, et al. Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report. Helicobactcr 1996; 1(4): 251-5.
30. 30 Miyaji H, Azuma T, Ito S, et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Alimentary Pharmacol Therapeutics 1997; 11(6): 1131-6.
31. 31 Perng CL, Kim JG, El-Zimaity HM, Osato MS, Graham DY. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. Digestive Dis Sci 1998; 43(3): 464-7.
32. 32 Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 1998; 93(3): 386-9.
33. 33 Vanderhulst RWM, Vanderende A, Homan A, Roorda P, Dankert J, Tytgat GNJ. Influence of metronidazole resistance one efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 1998; 42(2): 166-9.
34. 34 Graham DY, Hoffman J. Elzimaity HMT, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Alimentary Pharmacol Therapeutics 1997; 11(5): 935-8.
35. 35 De Boer WA, Etten R, Schneeberger PM. Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. Neth J Med 1998; 52(1): 10-5.
36. 36 De Boer WA, Driessen WMM, Tytgat GNJ. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Alimentary Pharmacol Therapeutics 1995; 9(6): 633-8.
37. 37 Borody TJ. Possibilities for Helicobacter pylori suppression/eradication. European J Gastroenterol Hepatol 1992; 4: S37-S40.
38. 38 Borody TJ, Brandl S, Andrews P, Jankiewicz E, Ostapowicz NH. pylori eradication failure (EF) - further treatment possibilities. Gastroenterol 1992; 102: A43(Abstract).
39. 39 De Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Heluohacter pylori infection. Lancet 1995; 345(8953): 817-20, 806-7.
40. 40 De Boer WA, Etten RJX, Schade RWB, Ouwehand ME, Schneeberger PM, Tytgat GNJ. 4-Day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am J Gastroenterol 1996; 91(9): 1778-82.
41. 41 De Boer WA, Driessen WMM, Jansz AR, Tytgat GNJ. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: Results of a randomized prospective single-centre study. European J Gastroenterol Hepatol 1995; 7(12): 1189-94.
42. 42 Houben MHMG, Schraffordt Koops HS, Rauws EAJ, et al. Efficacy of PPI-triple therapy in H. pylori (Hp) positive patients with ulcer disease versus patients with non-ulcer dyspepsia. Gut 1998; 43(Suppl. 2): A85(Abstract).
43. 43 Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37(4): 477-81.
44. 44 De Boer SY, Siem TH. Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection. Alimentary Pharmacol Therapeutics 1997; 11(6): 1119-21.
45. 45 de Boer WA, Etten RJ, Lai JY, Schneeberger PM, van de Wouw BA, Driessen WM, Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1996; 1(3): 145-50.
46. 46 Chan FKL, Yung MY, Ling TKW, Leung WK, Chung SCS, Sung JY. What is the true impact of metronidazole resistance on the efficacy of bismuth-based triple therapy? Gut 1998; 43(Suppl. 2): A84(Abstract).
47. 47 De Koster M, De Reuck M, Jonas C, et al. French triple works fine in Brussels. Gastroenterol 1997; 112(4): A99(Abstract).
48. 48 Van der Wouden EJ, Thijs JC, Kooy A, Kleibeuker JH. Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for II. pylori (Hp) infection. Spring meeting Netherlands Society of Gastroententerology 1998; Abstract.
49. 49 Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998; 54(1): 207-16.
50. 50 Vakil N, Fennerty M. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996; 91(2): 239-45.